Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CPL409116 in Healthy Volunteers
NCT04670757Phase 1Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CPL409116 in rheumatoid arthritis (RA), sponsored by Celon Pharma S.A. Primary endpoints: Maximum Tolerated Dose at 48 hours and Safety and Tolerability at 28 days. Started Dec 2020; status: completed.
02
Drugs
CPL409116
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04670757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670757.